These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 26569621

  • 1. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
    Costa C, Pereira S, Lima L, Peixoto A, Fernandes E, Neves D, Neves M, Gaiteiro C, Tavares A, Gil da Costa RM, Cruz R, Amaro T, Oliveira PA, Ferreira JA, Santos LL.
    PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
    [Abstract] [Full Text] [Related]

  • 2. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [Abstract] [Full Text] [Related]

  • 3. PI3K/AKT pathway activation in bladder carcinogenesis.
    Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y.
    Int J Cancer; 2014 Apr 15; 134(8):1776-84. PubMed ID: 24122582
    [Abstract] [Full Text] [Related]

  • 4. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
    Sun CH, Chang YH, Pan CC.
    Histopathology; 2011 Jun 15; 58(7):1054-63. PubMed ID: 21707707
    [Abstract] [Full Text] [Related]

  • 5. Nicotine Induces Tumor Growth and Chemoresistance through Activation of the PI3K/Akt/mTOR Pathway in Bladder Cancer.
    Yuge K, Kikuchi E, Hagiwara M, Yasumizu Y, Tanaka N, Kosaka T, Miyajima A, Oya M.
    Mol Cancer Ther; 2015 Sep 15; 14(9):2112-20. PubMed ID: 26184482
    [Abstract] [Full Text] [Related]

  • 6. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
    Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA.
    Cancer; 2007 Jun 01; 109(11):2257-67. PubMed ID: 17440983
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway.
    Wang Q, Zhang X, Song X, Zhang L.
    Arch Oral Biol; 2018 Dec 01; 96():74-79. PubMed ID: 30195142
    [Abstract] [Full Text] [Related]

  • 10. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y, Li L, Huang M, Duan C, Zhang L, Chen J.
    Cell Signal; 2014 Dec 01; 26(12):2782-92. PubMed ID: 25193113
    [Abstract] [Full Text] [Related]

  • 11. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
    Polo ML, Riggio M, May M, Rodríguez MJ, Perrone MC, Stallings-Mann M, Kaen D, Frost M, Goetz M, Boughey J, Lanari C, Radisky D, Novaro V.
    Oncotarget; 2015 Sep 08; 6(26):22081-97. PubMed ID: 26098779
    [Abstract] [Full Text] [Related]

  • 12. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
    Wu N, Du Z, Zhu Y, Song Y, Pang L, Chen Z.
    Technol Cancer Res Treat; 2018 Jan 01; 17():1533033818758772. PubMed ID: 29463194
    [Abstract] [Full Text] [Related]

  • 13. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H, Liu Q, Tang J, Xie Y, Xu X, Huang R, Zhang Y, Jin K, Sun B.
    Cell Physiol Biochem; 2017 Jan 01; 41(6):2289-2306. PubMed ID: 28456796
    [Abstract] [Full Text] [Related]

  • 14. Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases.
    Lima L, Neves M, Oliveira MI, Dieguez L, Freitas R, Azevedo R, Gaiteiro C, Soares J, Ferreira D, Peixoto A, Fernandes E, Montezuma D, Tavares A, Ribeiro R, Castro A, Oliveira M, Fraga A, Reis CA, Santos LL, Ferreira JA.
    Urol Oncol; 2017 Dec 01; 35(12):675.e1-675.e8. PubMed ID: 28911924
    [Abstract] [Full Text] [Related]

  • 15. Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours.
    Cotton S, Azevedo R, Gaiteiro C, Ferreira D, Lima L, Peixoto A, Fernandes E, Neves M, Neves D, Amaro T, Cruz R, Tavares A, Rangel M, Silva AMN, Santos LL, Ferreira JA.
    Mol Oncol; 2017 Aug 01; 11(8):895-912. PubMed ID: 28156048
    [Abstract] [Full Text] [Related]

  • 16. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
    Fahmy M, Mansure JJ, Brimo F, Yafi FA, Segal R, Althunayan A, Hicks J, Meeker A, Netto G, Kassouf W.
    Hum Pathol; 2013 Sep 01; 44(9):1766-72. PubMed ID: 23623586
    [Abstract] [Full Text] [Related]

  • 17. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).
    Li J, Dang Y, Gao J, Li Y, Zou J, Shen L.
    Med Oncol; 2015 Apr 01; 32(4):111. PubMed ID: 25757539
    [Abstract] [Full Text] [Related]

  • 18. Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.
    Sathe A, Nawroth R.
    Methods Mol Biol; 2018 Apr 01; 1655():335-350. PubMed ID: 28889395
    [Abstract] [Full Text] [Related]

  • 19. The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.
    Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P, Roa JC.
    Virchows Arch; 2014 Jul 01; 465(1):25-33. PubMed ID: 24844205
    [Abstract] [Full Text] [Related]

  • 20. Galectin-1 Overexpression Activates the FAK/PI3K/AKT/mTOR Pathway and Is Correlated with Upper Urinary Urothelial Carcinoma Progression and Survival.
    Su YL, Luo HL, Huang CC, Liu TT, Huang EY, Sung MT, Lin JJ, Chiang PH, Chen YT, Kang CH, Cheng YT.
    Cells; 2020 Mar 26; 9(4):. PubMed ID: 32225123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.